Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3

被引：9

作者：

Ma, Yaxi ^{[1
]}

Weimer, Joerg ^{[2
]}

Fredrik, Regina ^{[2
]}

Adam-Klages, Sabine ^{[3
]}

Sebens, Susanne ^{[4
]}

Caliebe, Amke ^{[5
,6
]}

Hilpert, Felix ^{[2
]}

Eckmann-Scholz, Christel ^{[2
]}

Arnold, Norbert ^{[2
]}

Schem, Christian ^{[2
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gynecol, Hangzhou 310009, Zhejiang, Peoples R China

[2] UKSH, Dept Obstet & Gynaecol, D-24105 Kiel, Germany

[3] UKSH, Dept Immunol, Kiel, Germany

[4] UKSH, Inst Expt Med, Clin Internal Med 1, Kiel, Germany

[5] Univ Kiel, Inst Med Informat & Stat, Kiel, Germany

[6] Univ Hosp Schleswig Holstein, Kiel, Germany

来源：

ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 2013年 / 288卷 / 01期

关键词：

Epithelial ovarian cancer; Aurora kinase inhibitor; Platinum; Polyploidy; Apoptosis; SKOV3; B KINASE; EXPRESSION; CARCINOMA; MANAGEMENT; SURVIVAL; GROWTH; TUMORS; P53;

D O I：

10.1007/s00404-013-2719-x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The treatment of ovarian tumors is carried out with platinum medicine which can lead to incompatibilities or resistances. Thus, it is of great interest to check new medicine suitability for its application. AZD1152 is an Aurora kinase inhibitor predominantly works against Aurora kinase B involved in the chromosome segregation. Cells become polyploidy and reduce the proliferation by this impairment. To investigate whether AZD1152, may play a role in the treatment of ovarian carcinoma we serving it to the cisplatinum-resistant cell line SKOV3 alone and in combination with platinum. We look at the proliferation, the ploidy, the phases of cell cycle and the apoptosis activity of the cells. We could show that the combination of both medicines in the preclinical experiment produces a working advantage.

引用

页码：173 / 182

页数：10